CareCloud, Inc. (CCLD) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial performance, with increased revenue guidance and improved cash flows. The strategic focus on AI and the successful integration of acquisitions indicate a promising future. Positive analyst sentiment in the Q&A, especially regarding AI monetization and market opportunities, supports a strong positive outlook. The company's strategic initiatives and robust financial metrics suggest a likely stock price increase exceeding 8%.
Key Financial Performance
Full Year Revenue $120.5 million, representing nearly 9% year-over-year growth. Reasons for growth include strategic acquisitions, expansion of market reach, and the successful launch of the flagship AI platform.
Q4 Revenue $34.4 million, up nearly 22% year-over-year. Reasons for growth include accelerating momentum and contributions from acquisitions like Medsphere.
GAAP Net Income (Full Year) $10.8 million, a year-over-year increase of more than 37%. Reasons for growth include multiyear transformation to sustainable profitability and operational improvements.
GAAP Earnings Per Share (Full Year) $0.10, marking the first full year of positive EPS since the 2014 IPO. Reasons include sustainable profitability and operational improvements.
GAAP Earnings Per Share (Q4) $0.04. Reasons include continued profitability and operational improvements.
Adjusted EBITDA (Full Year) $27.5 million with a 23% margin, up more than 14% year-over-year. Reasons include operational efficiency and revenue growth.
GAAP Operating Cash Flow (Full Year) $28.6 million, a 38% increase year-over-year. Reasons include improved profitability and operational efficiency.
GAAP Operating Cash Flow (Q4) $8.7 million, up 66% year-over-year. Reasons include improved profitability and operational efficiency.
Non-GAAP Free Cash Flow (Full Year) Approximately $20.5 million, compared to $13.2 million in 2024, representing growth of more than 500% from 2023. Reasons include improved financial flexibility and strategic acquisitions funded entirely from free cash flow.
Revenue from Medsphere Acquisition (Q4) $7.2 million. Reasons include strategic acquisition to expand capabilities and market reach.
Adjusted EBITDA (Q4) $7.7 million or 22% of revenue, an increase of 8% year-over-year. Reasons include operational efficiency and revenue growth.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
AI Platform Launch: Launched flagship AI platform, stratusAI Front Desk Agent, in December 2025, handling 80% of inbound scheduling-related calls for some clients. Also introduced stratusAI Voice Audit for call monitoring and CirrusAI Notes for clinical documentation.
AI Product Expansion: Developing AI-assisted medical coding and prior authorization capabilities, targeting release in 2026. Expanding AI applications across revenue cycle management and clinical workflows.
Market Expansion through Acquisitions: Acquired Medsphere Systems, entering the inpatient hospital market, and MAP App, a hospital benchmarking platform. These acquisitions expanded CareCloud's reach to hospital systems and health networks.
New Market Penetration: Entered the urgent care market with Wellsoft emergency documentation system, targeting approximately 11,000 urgent care facilities in the U.S.
Revenue Growth: Achieved $120.5 million in revenue for 2025, a 9% year-over-year growth. Q4 revenue was $34.4 million, up 22% year-over-year.
Profitability and Cash Flow: Reported GAAP net income of $10.8 million for 2025, a 37% increase year-over-year. Generated $28.6 million in GAAP operating cash flow, up 38% year-over-year.
Capital Structure Improvement: Converted 80% of Series A preferred shares into common stock, eliminating $7 million in annual dividend obligations. Fully repaid Provident Bank credit line by year-end 2025.
Strategic Acquisitions: Executed acquisitions at less than 1x revenue multiples, funded entirely through free cash flow, with no common shareholder dilution. Focused on expanding capabilities and market reach.
AI-Centric Strategy: Positioned AI as a core growth driver, integrating AI capabilities into newly acquired platforms and targeting operational efficiencies and revenue improvements.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Conditions: The healthcare technology market is at an inflection point, with providers actively seeking AI integration. However, the competitive landscape and the need for rapid AI adoption could pose challenges.
Regulatory Hurdles: AI in healthcare must comply with healthcare-specific compliance and accuracy standards, which could slow down deployment and adoption.
Supply Chain Disruptions: The integration of new acquisitions like Medsphere and MAP App into CareCloud's operations could face challenges, particularly in aligning supply chain and operational workflows.
Economic Uncertainties: The company’s growth strategy relies heavily on acquisitions and AI investments, which could be impacted by broader economic conditions or funding constraints.
Strategic Execution Risks: The success of the AI Center of Excellence and the integration of AI into acquired platforms depend on effective execution. Failure to deliver measurable outcomes could undermine client trust and market position.
Competitive Pressures: The healthcare IT market is highly competitive, and CareCloud’s ability to maintain its market position depends on the successful scaling of its AI solutions and cross-selling opportunities.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for 2026: CareCloud expects revenue of $128 million to $130 million for 2026, reflecting continued growth.
Adjusted EBITDA Guidance for 2026: The company projects adjusted EBITDA of $29 million to $31 million, indicating margin expansion.
GAAP EPS Guidance for 2026: CareCloud anticipates GAAP EPS of $0.20 to $0.23 per share, representing an increase of more than 100% over 2025.
AI Product Expansion: The company plans to expand its AI product suite, including AI-assisted coding and prior authorization AI, targeted for release in 2026.
AI Monetization and Cross-Selling: CareCloud aims to execute cross-sell opportunities by integrating AI products into newly acquired platforms and existing relationships, particularly in hospital systems.
Acquisition Strategy for 2026: The company expects to remain active in M&A, targeting complementary acquisitions that extend its reach and benefit from its AI capabilities.
AI Center of Excellence Development: CareCloud will continue to deepen its clinical data sets, develop proprietary models, and selectively partner with AI infrastructure providers to enhance its AI capabilities.
Market Position and Growth Drivers: The company will leverage its dual platform footprint in ambulatory and inpatient markets to drive organic growth and acquisition synergies, focusing on ambulatory cross-selling, deeper hospital penetration, and AI monetization.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Resumption of Dividends: CareCloud resumed dividends on its preferred shares at the beginning of 2025.
Double Dividends: The company plans to begin paying double dividends on its Series B preferred stock starting in 2026 to address accumulated arrearages.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How is the company planning to monetize AI in 2026?
A:The company plans to integrate AI into acquired software platforms, making them more competitive and attractive. They are also using AI and automation to handle back-office processing, which drives margins. The strategy includes improving AI in backend operations, integrating AI into existing product suites, and developing new AI applications.
Q:What was behind the recent contract wins and how does the company view future opportunities?
A:The company expanded its sales and marketing team by 2-3x, focusing on cross-selling and new opportunities. They see significant potential in expanding wallet share with existing customers, particularly those acquired through recent transactions. New wins include Wellsoft EHR for emergency departments and a supply chain product.
Q:What is the market opportunity for the front-end AI product launched in December, and what are the early indications of interest?
A:The market opportunity for the stratusAI product is estimated at $4 billion. Early adoption has been encouraging, with a robust deployment pipeline among existing ambulatory clients. The company plans to share more specific adoption metrics as they progress through 2026.
Q:How should investors view CareCloud's exposure to AI disruption versus being an AI beneficiary?
A:CareCloud is positioned as an AI beneficiary due to its deep industry moats, regulatory barriers, and proprietary data. Unlike horizontal SaaS tools, their AI products require rigorous testing and certification. The company integrates AI into its technology backbone, which drives revenue cycle management services and adds value to client relationships.
Q:What assumptions are built into the 2026 guidance and how does the company view growth beyond next year?
A:The 2026 guidance assumes top-line growth, integration savings from acquisitions, AI efficiencies, and elimination of preferred dividend obligations. The company expects to expand margins as they scale and continue to invest in AI and M&A opportunities.
Q:Does the AI technology save money operationally and increase margins?
A:Yes, AI technology has enabled the company to increase revenue while reducing the number of employees. This has been a significant driver of margin improvement, and the company expects these efficiencies to grow as AI adoption progresses.
Q:What are the focuses for the use of excess cash flow if no acquisitions are made?
A:The company plans to use excess cash flow for acquisitions, enhancing capital structure, and investing in AI to expand software product capabilities and client responsibilities.
Q:Who are the competitors for CareCloud in its business areas?
A:Competitors in the EHR space include eClinicalWorks, AdvancedMD, and athenahealth. In AI, competitors vary by product, with SoundHound being a notable competitor for certain AI functionalities. However, CareCloud's vertical integration provides a competitive advantage.
Q:What are the expectations for CapEx and capitalized software spending in the 2026 outlook?
A:CapEx and capitalized software spending are expected to remain the same or slightly lower compared to the previous year.
Q:Does the 2026 guidance include unannounced acquisitions?
A:No, the 2026 guidance does not include any unannounced material acquisitions.
Q:Will AI adoption provide benefits on the expense side?
A:Yes, AI adoption is expected to reduce expenses and expand margins. The company believes it can achieve its AI goals with a leaner team than initially envisioned.
Q:Review of Unclear Management Responses
A:Management avoided providing specific client counts for the early adoption of the stratusAI product, citing plans to share more metrics in the future. Additionally, they did not disclose detailed financial assumptions for CapEx and capitalized software spending, only stating it would be similar or slightly lower than the previous year.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI Center
AI capability
AI health
AI platform
App hospital
Center Excellence
CirrusAI Notes
Desk Agent
HFMA
MAP App
Series stock
Voice Audit
access
acquisition opportunity
authorization
capital structure
care setting
conversion
credit cash
denial
department
emergency
enhancement
health care
line credit
market position
portfolio
reach
relationship
road map
staff
stratusAI
suite
supply chain
CCLD Transcript
CareCloud, Inc. (CCLD) Q1 2026 Earnings Call Transcript
Positive5-7
The earnings call highlights strong financial guidance, AI product expansion, and strategic M&A plans, reflecting a positive outlook. The Q&A session supports this with positive feedback on AI products and a clear strategy for margin improvement and customer acquisition. Despite some vagueness in management responses, the overall sentiment is positive, indicating potential stock price appreciation.
CareCloud, Inc. (CCLD) Q4 2025 Earnings Call Transcript
Positive3-12
The earnings call highlights strong financial performance, with increased revenue guidance and improved cash flows. The strategic focus on AI and the successful integration of acquisitions indicate a promising future. Positive analyst sentiment in the Q&A, especially regarding AI monetization and market opportunities, supports a strong positive outlook. The company's strategic initiatives and robust financial metrics suggest a likely stock price increase exceeding 8%.
CareCloud, Inc. (CCLD) Q3 2025 Earnings Call Transcript
Positive11-6
The earnings call highlights strong financial performance with a 9% revenue increase, improved GAAP EPS, and increased adjusted EBITDA. AI initiatives and product development show promise, with successful acquisitions enhancing market reach. The company maintains strong guidance and is strategically positioned for growth. The Q&A section reflects confidence in strategy execution and future profitability. Overall, despite some economic uncertainties and integration risks, the positive financial metrics and strategic initiatives suggest a positive stock price movement in the short term.
CareCloud, Inc. (CCLD) Q2 2025 Earnings Call Transcript
Positive8-5
The earnings call summary reveals strong financial performance with positive GAAP EPS, increased adjusted EBITDA, and robust free cash flow. The company has a strategic focus on AI, enhancing product competitiveness and operational efficiency, which is positively received by customers. Despite a slight revenue decline due to a non-recurring item, the overall financial health is strong. The Q&A section supports the positive outlook with plans for growth through AI and M&A. Therefore, the stock price is likely to see a positive movement in the next two weeks.
CCLD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
